Although studies have clearly demonstrated the therapeutic potential of inhibiting LDHA in cancer patients, most current inhibitors (Table 3) affect more than one of the LDH genes, have low potency and require unacceptably high doses (which may also be affecting other unknown nonspecific targets) to achieve the desired effect and therefore are not suitable for clinical use. The gene discussed is LDHA; the disease is cancer.